Dataset Information

Targeting phosphatase-dependent proteoglycan switch for rheumatoid arthritis therapy.

ABSTRACT: Despite the availability of several therapies for rheumatoid arthritis (RA) that target the immune system, a large number of RA patients fail to achieve remission. Joint-lining cells, called fibroblast-like synoviocytes (FLS), become activated during RA and mediate joint inflammation and destruction of cartilage and bone. We identify RPTP?, a transmembrane tyrosine phosphatase, as a therapeutic target for FLS-directed therapy. RPTP? is reciprocally regulated by interactions with chondroitin sulfate or heparan sulfate containing extracellular proteoglycans in a mechanism called the proteoglycan switch. We show that the proteoglycan switch regulates FLS function. Incubation of FLS with a proteoglycan-binding RPTP? decoy protein inhibited cell invasiveness and attachment to cartilage by disrupting a constitutive interaction between RPTP? and the heparan sulfate proteoglycan syndecan-4. RPTP? mediated the effect of proteoglycans on FLS signaling by regulating the phosphorylation and cytoskeletal localization of ezrin. Furthermore, administration of the RPTP? decoy protein ameliorated in vivo human FLS invasiveness and arthritis severity in the K/BxN serum transfer model of RA. Our data demonstrate that FLS are regulated by an RPTP?-dependent proteoglycan switch in vivo, which can be targeted for RA therapy. We envision that therapies targeting the proteoglycan switch or its intracellular pathway in FLS could be effective as a monotherapy or in combination with currently available immune-targeted agents to improve control of disease activity in RA patients.

SUBMITTER: Doody KM

PROVIDER: S-EPMC4458332 | biostudies-literature | 2015 May

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Targeting phosphatase-dependent proteoglycan switch for rheumatoid arthritis therapy.

Doody Karen M KM Stanford Stephanie M SM Sacchetti Cristiano C Svensson Mattias N D MN Coles Charlotte H CH Mitakidis Nikolaos N Kiosses William B WB Bartok Beatrix B Fos Camille C Cory Esther E Sah Robert L RL Liu-Bryan Ru R Boyle David L DL Arnett Heather A HA Mustelin Tomas T Corr Maripat M Esko Jeffrey D JD Tremblay Michel L ML Firestein Gary S GS Aricescu A Radu AR Bottini Nunzio N

Science translational medicine 20150501 288

Despite the availability of several therapies for rheumatoid arthritis (RA) that target the immune system, a large number of RA patients fail to achieve remission. Joint-lining cells, called fibroblast-like synoviocytes (FLS), become activated during RA and mediate joint inflammation and destruction of cartilage and bone. We identify RPTPσ, a transmembrane tyrosine phosphatase, as a therapeutic target for FLS-directed therapy. RPTPσ is reciprocally regulated by interactions with chondroitin sulf ...[more]

PMID: 25995222

Similar Datasets

Project description:BackgroundRheumatoid arthritis (RA) is an autoimmune inflammatory disease affecting the joints. Anti-citrullinated protein antibodies (ACPA) are frequently found in RA. Previous studies identified a citrullinated epitope in cartilage proteoglycan (PG) aggrecan that elicited pro-inflammatory cytokine production by RA T cells. We recently reported the presence of ACPA-reactive (citrullinated) PG in RA cartilage. Herein, we sought to identify additional citrullinated epitopes in human PG that are recognized by T cells or antibodies from RA patients.MethodsWe used mice with PG-induced arthritis (PGIA) as a screening tool to select citrulline (Cit)-containing PG peptides that were more immunogenic than the arginine (R)-containing counterparts. The selected peptide pairs were tested for induction of pro-inflammatory T-cell cytokine production in RA and healthy control peripheral blood mononuclear cell (PBMC) cultures using ELISA and flow cytometry. Anti-Cit and anti-R peptide antibodies were detected by ELISA.ResultsSplenocytes from mice with PGIA exhibited greater T-cell cytokine secretion in response to the Cit than the R version of PG peptide 49 (P49) and anti-P49 antibodies were found in PGIA serum. PBMC from ACPA+ and ACPA- RA patients, but not from healthy controls, responded to Cit49 with robust cytokine production. High levels of anti-Cit49 antibodies were found in the plasma of a subset of ACPA+ RA patients. Another PG peptide (Cit13) similar to the previously described T-cell epitope induced greater cytokine responses than R13 by control (but not RA) PBMC, however, anti-Cit13 antibodies were rarely detected in human plasma.ConclusionsWe identified a novel citrullinated PG epitope (Cit49) that is highly immunogenic in mice with PGIA and in RA patients. We also describe T-cell and antibody reactivity with Cit49 in ACPA+ RA. As citrullinated PG might be present in RA articular cartilage, Cit PG epitope-induced T-cell activation or antibody deposition may occur in the joints of RA patients.

Dataset Information

Targeting phosphatase-dependent proteoglycan switch for rheumatoid arthritis therapy.

Publications

Targeting phosphatase-dependent proteoglycan switch for rheumatoid arthritis therapy.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets